Zim Laboratories Ltd PE Ratio

Home

Insights

Zim Laboratories Ltd P/E Ratio

₹ 0.1 Cr

Volume transacted

11.9 K

stocks traded

Last Updated time: 26 Jul 9.00 AM

Zim Laboratories Ltd

NSE: ZIMLABORATORIES

32.3

Last updated : 26 Jul 9.00 AM

Key Highlights

The P/E Ratio of Zim Laboratories Ltd is 32.3 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Zim Laboratories Ltd changed from 13.1 on March 2019 to 27 on March 2024 . This represents a CAGR of 12.81% over 6 years. a1#The Latest Trading Price of Zim Laboratories Ltd is ₹ 114.35 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Zim Laboratories Ltd changed from ₹ 201.82 crore on March 2019 to ₹ 465.33 crore on March 2024 . This represents a CAGR of 14.94% over 6 years. a1#The Revenue of Zim Laboratories Ltd changed from ₹ 94.64 crore to ₹ 119.4 crore over 8 quarters. This represents a CAGR of 12.32% a1#The EBITDA of Zim Laboratories Ltd changed from ₹ 13.08 crore to ₹ 17.18 crore over 8 quarters. This represents a CAGR of 14.61% a1#The Net Pr of Zim Laboratories Ltd changed from ₹ 5.15 crore to ₹ 8.09 crore over 8 quarters. This represents a CAGR of 25.33% a1#The Dividend Payout of Zim Laboratories Ltd changed from 5.09 % on March 2019 to 0 % on March 2024 . This represents a CAGR of -100.00% over 6 years. a1#

Open Demat Account

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Historical P/E Ratio of Zim Laboratories Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Zim Laboratories Ltd

Period
Mar '19	13.1
Mar '20	27.4
Mar '21	16.1
Mar '22	17.8
Mar '23	14.4
Mar '24	27

Company Fundamentals for Zim Laboratories Ltd

Market Cap

₹ 557 Cr

EPS

₹ 3.5

P/E Ratio (TTM) *

32.3

P/B Ratio (TTM) *

2.3

Day’s High

₹ 114.75

Day’s Low

₹ 109.65

DTE *

0.5

ROE *

7.2

52 Week High

₹ 151.75

52 Week Low

₹ 89.9

ROCE *

8.7

* All values are consolidated

Last Updated time: 26 Jul 9.00 AM

* All values are consolidated

Last Updated time: 26 Jul 9.00 AM

Zim Laboratories Ltd

NSE: ZIMLABORATORIES

PRICE

₹ 114.35

3.60 (3.25%)

Last updated : 25 Jul 15:30

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

* All values are in Rupees

SWOT Analysis Of Zim Laboratories Ltd

Strength

Weakness

Opportunity

Threats

Asset Value vs Market Value of Zim Laboratories Ltd

Market Value

₹ 557

Asset Value

₹ 229

1.4 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company Name	PE	Market Cap (INR Cr.)
Zim Laboratories Ltd	32	557
Sun Pharmaceuticals Industries Ltd	40	399,537
Zydus Lifesciences Ltd	31	121,312
Cipla Ltd	28	121,120
Divis Laboratories Ltd	75	120,782
Dr Reddys Laboratories Ltd	20	114,348

Key Valuation Metric of Zim Laboratories Ltd

Earnings

₹17 Cr

32.3 X

PE Ratio

Market Cap

₹557.18Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.

P/E Ratio Formula

P/E ratio = (CMP of share/ Earning per share)

Types of Price to Earning Ratio

1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

₹17 Cr

32.3 X

PE Ratio

Market Cap

₹557.18Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.

P/E Ratio Formula

P/E ratio = (CMP of share/ Earning per share)

Types of Price to Earning Ratio

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Zim Laboratories Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Zim Laboratories Ltd

Period
Mar '19	202
Mar '20	91
Mar '21	118
Mar '22	260
Mar '23	353
Mar '24	465

* All values are a in ₹crore

Historical Revenue of Zim Laboratories Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Zim Laboratories Ltd

Period
Jun '22	95
Sep '22	101
Dec '22	103
Mar '23	106
Jun '23	69
Sep '23	87
Dec '23	97
Mar '24	119

* All values are a in ₹crore

Historical EBITDA of Zim Laboratories Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Zim Laboratories Ltd

Period
Jun '22	13
Sep '22	14
Dec '22	16
Mar '23	16
Jun '23	6
Sep '23	11
Dec '23	13
Mar '24	17

* All values are a in ₹crore

Historical Net Profit of Zim Laboratories Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Zim Laboratories Ltd

Period
Jun '22	5
Sep '22	5
Dec '22	7
Mar '23	7
Jun '23	0
Sep '23	4
Dec '23	5
Mar '24	8

* All values are a in ₹crore

Historical Dividend Payout of Zim Laboratories Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Zim Laboratories Ltd

Period
Mar '19	5
Mar '20	0
Mar '21	0
Mar '22	0
Mar '23	0
Mar '24	0

* All values are a in %

About Zim Laboratories Ltd

Zim Laboratories Ltd was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in the State of Maharashtra. The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Maharashtra, Mumbai. The Company is engaged in the manufacturing of formulation on drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The Pharma Industry is dominated by Multinationals, Large Indian companies and in the lower end of the market large number of units mainly in the SSI sector. During the year 2019-20, ZIM Health Technologies Limited was acquired thereby resulting as a wholly owned subsidiary of the company . SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia. In 2023, the Company launched Thinoral (Patented Oral Thin Film technology) as an alternate drug delivery platform across RoW/ Pharmerging Markets and EU.